BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:IFx-2.0 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of IFx-2.0\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06947928-10880@assetmemo.bio
DTSTAMP:20261121T005843Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:IFx-2.0: Phase 2/3 readout est. (NCT06947928)
DESCRIPTION:IFx-2.0\, phase 2/3\, Merkel Cell Carcinoma.\nStudy: Placebo-Co
 ntrolled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibi
 tor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma\
 nEstimated primary completion: 31 March 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ifx-2-0#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06947928
URL:https://assetmemo.bio/drug/ifx-2-0#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940440-10880@assetmemo.bio
DTSTAMP:20261121T005843Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:IFx-2.0: Phase 1 readout est. (NCT06940440)
DESCRIPTION:IFx-2.0\, phase 1\, Merkel Cell Carcinoma.\nStudy: IFx-Hu2.0 As
  An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel C
 ell Carcinoma (MCC)\nEstimated primary completion: April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ifx-2-0#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06940440
URL:https://assetmemo.bio/drug/ifx-2-0#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
